Form 4: BioXcel Therapeutics Executive VP Vincent O'Neill Reports Stock Transactions
SEC Form 4
Executive Vice President of BioXcel Therapeutics, Vincent O'Neill, reports the acquisition and disposition of common stock and restricted stock units.
Summary
- On June 14, 2024, Vincent O'Neill, Executive Vice President of BioXcel Therapeutics, acquired 521 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- On June 17, 2024, O'Neill disposed of 155 shares of common stock at a price of $1.285 per share.
- Following these transactions, O'Neill directly owns 3,524 shares of common stock and 3,648 Restricted Stock Units.
- The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023.
- The RSUs vest in installments, subject to continuous employment with BioXcel Therapeutics.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment, but rather provides information about executive stock transactions.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to the market regarding the buying and selling activities of company executives and directors.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company executives as an indicator of management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| 2023-12-15 | Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-06-14 | Acquisition of 521 shares of common stock through RSU vesting. |
| 2024-06-17 | Disposition of 155 shares of common stock at $1.285 per share. |
| 2024-06-18 | Date of Form 4 filing. |
Keywords
BioXcel Therapeutics, BTAI, Vincent O'Neill, Form 4, Stock Transaction, Restricted Stock Units, Rule 10b5-1, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.